Neurogene Inc.
NASDAQ: NGNE0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- NASDAQ Global Market
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Rachel L. McMinn
- Employees
- 107
- Headquarters
- New York City, United States
- IPO year
- 2014
- Market cap
- $475.2M
- Website
- https://www.neurogene.com
Loading NGNE…
Loading profile data…Frequently asked questions about NGNE
What does Neurogene Inc. (NGNE) do?
Neurogene Inc. is dedicated to engineering transformative genetic treatments for individuals and their families grappling with debilitating neurological conditions. Its current pipeline prominently features two key investigational therapies: NGN-401, an AAV9 gene therapy specifically targeting Rett syndrome, and NGN-101, which is being developed...
Where does NGNE trade?
Neurogene Inc. (NGNE) trades on the NASDAQ Global Market.
What sector is NGNE in?
Neurogene Inc. (NGNE) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of Neurogene Inc.?
Rachel L. McMinn is the chief executive officer of Neurogene Inc. (NGNE).
Where is Neurogene Inc. headquartered?
Neurogene Inc. is headquartered in United States.
Does NGNE pay a dividend?
Neurogene Inc. (NGNE) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did NGNE go public?
Neurogene Inc. (NGNE) completed its initial public offering in 2014.